Avanir Pharmaceuticals

Avanir Pharmaceuticals is a biopharmaceutical company founded in1988 focused primarily on developing innovative treatments for central nervous system disorders such as pseudobulbar affect and neuropsychiatric symptoms related to Alzheimer's disease and other neurological conditions. Its flagship commercial product is Nuedexta®, approved for pseudobulbar affect since2011. The company was acquired by Japanese global healthcare giant Otsuka Pharmaceutical Co., Ltd.in2015and now operates as an integrated subsidiary within the Otsuka group headquartered at Aliso Viejo California.

Its pipeline includes advanced clinical stage programs like AVP‑786—a deuterated formulation designed to treat agitation associated with Alzheimer's disease currently undergoing multiple pivotal Phase III trials worldwide with promising efficacy signals demonstrated so far.

This positions Avanir firmly within the specialty pharmaceutical sector focusing exclusively on CNS therapeutic areas using proprietary small molecule combinations enhanced through novel chemical modifications such as deuteration technology.